susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing

susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing

Background

Bibliographic Details
Published:
Online Access:	http://hdl.handle.net/2047/d20001016

Similar Items

The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing.
by: Rosario Diaz-Gonzalez, et al.
Published: (2011-08-01)

A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
by: Shujie Yang, et al.
Published: (2011-01-01)

Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma
by: Angelica Benavides-Serrato, et al.
Published: (2020-01-01)

All PI3Kinase signaling is not mTOR: Dissecting mTOR-dependent and independent signaling pathways in T cells
by: Christopher Jordan Gamper, et al.
Published: (2012-10-01)

PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
by: Khanh B. Tran, et al.
Published: (2021-02-01)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
by: Gillian Moore, et al.
Published: (2021-04-01)

mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
by: Sofie Mohlin, et al.
Published: (2019-08-01)

Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
by: Sofie Mohlin, et al.
Published: (2020-01-01)

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
by: Tian Tian, et al.
Published: (2019-02-01)

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
by: Petra Hillmann, et al.
Published: (2019-11-01)

A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
by: Hiroshi Fukamachi, et al.
Published: (2019-03-01)

Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
by: Kasun Wanigasooriya, et al.
Published: (2020-05-01)

mTOR signaling cascade in psoriatic disease: Double kinase mtor inhibitor a novel therapeutic target
by: Smriti K Raychaudhuri, et al.
Published: (2014-01-01)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
by: Chiara Tarantelli, et al.
Published: (2020-02-01)

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
by: Nazanin Momeni Roudsari, et al.
Published: (2021-08-01)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging Therapeutic Opportunities
by: Paul A Hubbard, et al.
Published: (2014-12-01)

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.
by: Sharmila Mallya, et al.
Published: (2014-01-01)

PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
by: Aziz Ur Rehman Aziz, et al.
Published: (2018-02-01)

Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment
by: Moorthy, Ganesh
Published: (2015)

Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
by: Paolo Uva, et al.
Published: (2021-06-01)

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes
by: Feinstein Douglas L, et al.
Published: (2011-01-01)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
by: Samantha Exner, et al.
Published: (2021-02-01)

Role of mTOR Inhibitors in Kidney Disease
by: Moto Kajiwara, et al.
Published: (2016-06-01)

PI3K/AKT/mTOR pathway in Angiogenesis
by: Jayashree eKarar, et al.
Published: (2011-12-01)

Targeting PI3K/mTOR signaling in cancer
Published: (2014)

Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities
by: Tan Li, et al.
Published: (2014-10-01)

mTOR regulation of lymphoid cells in immunity to pathogens
by: Rachael eKeating, et al.
Published: (2016-05-01)

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics
by: Shraddha Parate, et al.
Published: (2021-03-01)

Carcinoma da bexiga: via de sinalização PI3K/Akt/mTOR e inibidores do mTOR
by: Maria do Céu dos Santos Silva Costa
Published: (2019)

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against <i>Leishmania donovani</i> and <i>Trypanosoma brucei</i>
by: Trong-Nhat Phan, et al.
Published: (2020-04-01)

Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01)

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
by: Andrew M. Courtwright, et al.
Published: (2017-01-01)

mTOR Inhibitors in Advanced Biliary Tract Cancers
by: Chao-En Wu, et al.
Published: (2019-01-01)

Small-molecule inhibitors of mTOR and DNA-PK
by: Payne, Sara Lauren
Published: (2010)

Cancer and mTOR inhibitors in kidney transplantation recipients
by: Chih-Chin Kao, et al.
Published: (2018-11-01)

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
by: Chao Dong, et al.
Published: (2021-03-01)